New dosing regimen for durvalumab (Imfinzi) for advanced non-small cell lung cancer (NSCLC) approved in UK and EU

The additional dosing option of 1,500mg every four weeks (current SPC dose 10mg/kg every 2 weeks) has been approved for use in adults with advanced NSCLC whose tumours cannot be surgically removed, to help reduce the frequency of hospital visits while continuing treatment.

Source:

Reuters Health